secwatch.observer — SEC 8-K summary
======================================

Issuer:     Lyell Immunopharma, Inc. (LYEL)
CIK:        0001806952
Form:       8-K
Filed at:   2026-03-09T23:59:59+00:00
Accession:  0001193125-26-097615
Event type: leadership
Sentiment:  neutral
Materiality: 0.50
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Lyell Immunopharma appoints Smital Shah as Chief Financial and Business Officer
-------------------------------------------------------------------------------

- Smital Shah appointed CFO and principal financial officer, effective March 9, 2026.
- Initial base salary $500,000; target annual bonus up to 50% of base salary.
- Granted option for 140,000 shares under 2021 Equity Incentive Plan; vesting 25% at 1 year then monthly.
- Shah previously provided consulting to Lyell since Feb 2026; prior roles at ProQR, Gilead, and investment banks.
- Will participate in Officer Severance Plan as Tier I Employee.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1806952/000119312526097615/0001193125-26-097615-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1806952/000119312526097615/d84786d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-097615

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer